Artemis Investment Management LLP Buys Shares of 226,845 Biogen Inc. $BIIB

Key Points

• Artemis Investment Management LLP opened a new position in Biogen, buying 226,845 shares worth about $39.9 million — roughly 0.15% of the company at quarter-end — as part of broad institutional ownership (87.93%).
• Biogen beat Q1 estimates (EPS $3.57 vs. $2.95; revenue $2.48B vs. $2.29B) and set FY2026 EPS guidance of 14.25–15.25, prompting mixed analyst reactions (average rating "Hold", average price target $214.23) while the Apellis transaction will create a ~$120–$130M 2026 headwind.

Artemis Investment Management LLP acquired a new position in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 226,845 shares of the biotechnology company's stock, valued at approximately $39,922,000. Artemis Investment Management LLP owned approximately 0.15% of Biogen at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the company. Convergence Investment Partners LLC purchased a new position in Biogen during the third quarter valued at $1,342,000. Caprock Group LLC purchased a new position in Biogen during the third quarter valued at $742,000. Leuthold Group LLC purchased a new position in Biogen during the third quarter valued at $3,294,000. Generali Investments Management Co LLC raised its stake in Biogen by 408.2% during the third quarter. Generali Investments Management Co LLC now owns 9,970 shares of the biotechnology company's stock valued at $1,397,000 after buying an additional 8,008 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in Biogen by 9.8% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 67,010 shares of the biotechnology company's stock valued at $9,387,000 after buying an additional 5,987 shares during the last quarter. Institutional investors own 87.93% of the company's stock.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. HSBC lifted their price objective on Biogen from $143.00 to $150.00 and gave the company a "reduce" rating in a research note on Tuesday, March 17th. JPMorgan Chase & Co. lifted their price objective on Biogen from $175.00 to $185.00 and gave the company a "neutral" rating in a research note on Thursday, April 23rd. Stifel Nicolaus lifted their price objective on Biogen from $202.00 to $214.00 and gave the company a "buy" rating in a research note on Friday, February 6th. Citigroup lifted their price objective on Biogen from $190.00 to $200.00 and gave the company a "neutral" rating in a research note on Friday. Finally, Sanford C. Bernstein lowered their price objective on Biogen from $201.00 to $200.00 in a research note on Thursday. Thirteen research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $214.23.

Biogen Stock Performance

NASDAQ:BIIB opened at $187.06 on Friday. The stock has a 50-day simple moving average of $184.52 and a two-hundred day simple moving average of $176.06. Biogen Inc. has a 52-week low of $115.25 and a 52-week high of $202.41. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.03 and a current ratio of 3.06. The firm has a market capitalization of $27.45 billion, a PE ratio of 20.07, a P/E/G ratio of 1.55 and a beta of 0.16.

Biogen (NASDAQ:BIIB - Get Free Report) last released its quarterly earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.95 by $0.62. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The business had revenue of $2.48 billion during the quarter, compared to analyst estimates of $2.29 billion. During the same quarter in the previous year, the company posted $3.02 earnings per share. Biogen's revenue for the quarter was up 1.9% on a year-over-year basis. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. Analysts forecast that Biogen Inc. will post 15.26 EPS for the current year.

Biogen News Roundup

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Q1 beat driven by growth from newer drugs (Leqembi, Skyclarys) and upbeat revenue/profit metrics that underpin optimism about Biogen’s growth portfolio. Bristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlook
• Positive Sentiment: RBC raised its price target to $222 and maintained an Outperform rating, signaling strong analyst conviction and upside potential for BIIB. RBC raises PT to $222
• Positive Sentiment: H.C. Wainwright reiterated a Buy and lifted its PT to $237, citing reduced risk on BIIB080 (Alzheimer’s) — a bullish signal for upside from pipeline progress. H.C. Wainwright reiterates Buy, PT $237
• Positive Sentiment: TD Cowen initiated / affirmed a Buy with a $215 price target, citing strong Q1, pipeline progress and the Apellis deal as supportive factors. TD Cowen Buy, PT $215
• Positive Sentiment: Rothschild & Co Redburn nudged its PT up to $190 (small upside), reflecting modestly improved near-term views. Rothschild raises PT to $190
• Neutral Sentiment: BMO kept a Market Perform/Hold rating with an unchanged $196 target, signaling that some analysts see constrained near-term growth despite the beat. BMO maintains Hold, PT $196
• Neutral Sentiment: Several analyst notes and commentary highlight mixed takeaways: firms generally raised forecasts after the Q1 beat but some also trimmed FY2026 EPS expectations, producing varied buy/hold calls. Analysts boost forecasts after Q1
• Negative Sentiment: Biogen disclosed the Apellis transaction will create a ~$120M–$130M other‑income headwind in 2026 (non‑GAAP EPS accretion expected in 2027), creating a near‑term earnings drag that pressured sentiment. Apellis deal impact
• Negative Sentiment: Sanford C. Bernstein trimmed its PT slightly from $201 to $200 — a modest negative signal that may contribute to profit-taking amid mixed analyst reactions. Bernstein trims PT to $200

Insider Transactions at Biogen

In other Biogen news, insider Priya Singhal sold 2,660 shares of the business's stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $199.83, for a total transaction of $531,547.80. Following the completion of the sale, the insider owned 8,043 shares of the company's stock, valued at approximately $1,607,232.69. The trade was a 24.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 0.18% of the company's stock.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer's disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company's marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.